Delays in time to first lenalidomide prescription fill for multiple myeloma. Preliminary results of a combined home and rural outpatient clinic-based infusion program through the Veterans Health ...
Phase 2 evaluation of the nilotinib-paclitaxel combination in patients with rare solid tumors: Rapid analysis and response evaluation of combination anti-neoplastic agents in rare tumors trial 1 (RARE ...
A new ultra-high-throughput sequencing platform boosts output, speeds turnaround, and improves genome coverage. It reduces costs, broadens clinical applications, and accelerates large-scale genomics ...
Generation Sequencing (NGS) market is set to surge from $14.79 billion in 2025 to $56.25 billion by 2033, with a robust CAGR of 18.17%. Key drivers include advancements in sequencing technologies, ...
Twice the output, half the runtime, and half the footprint of the UG 100® with greater flexibility and improved genomic ...
BURBANK, Calif. (KABC) -- Cancer is not a welcome diagnosis, but breakthroughs in genetic sequencing and immunotherapy are making some cancers easier to treat than others. A local father and ...
Life sciences and diagnostics company Revvity has had a busy couple of years, playing a major role in the next-generation sequencing-based screening of newborns to better enable healthcare ...
Like many cancer patients, Michael Wolff wanted answers. But, like many cancer patients in 2015, he wasn't getting them. After years of lymphoma treatment, the renowned jazz musician was still sick ...
Element Biosciences AVITI24 5D Multiomic and AVITI next generation sequencing systems are designed to make high-performance genomics accessible to all. With its combination of accuracy, flexibility, ...
Breast cancer remains one of the most prevalent and life-threatening forms of cancer, impacting millions worldwide. This malignancy's heterogeneity and complexity have long posed significant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results